News

Whether investors realize it or not, the ruling is huge for Google's parent company and its stock.

Trump has called AI risks a hoax while Amodei, Altman and Musk want a slowdown

The team digs into the details of the settlement and how it will impact Meta.

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Meta Platforms will pay up to $18 billion and significantly overhaul its teen-usage policies across its platforms.

The Justice Department once threatened Walmart's pharmacies with billions in civil penalties over opioid prescriptions. What prosecutors actually walked away with tells a very different story about who held the leverage.

The chip giant stepped back from the AI Compute Partnership program last week, less than two months after announcing it in July

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...

Can the company navigate these legal troubles?

NHTSA just labeled over 135,000 Ford vehicles an unreasonable safety risk, and the agency has not finished with Ford yet. With 36 recalls already logged in 2026 and a billion dollars in promised warranty savings on the line, the pressure on Jim Farley is reaching a breaking point.

A Massachusetts couple who ran an e-commerce newsletter started receiving anonymous packages containing live cockroaches, a fetal pig, and death threats, and it took years before the full scope of who orchestrated the campaign against them came to light.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Wolfspeed’s patent infringement lawsuit against Navitas Semiconductor (NVTS) has quickly become a key focus for investors, with allegations centered on gallium nitride and silicon carbide products that sit at the heart of both companies’ power chip offerings. See our latest analysis for Navitas Semiconductor. Recent trading in Navitas Semiconductor reflects this tension, with the share price at $13.36 after a 1-day share price return that declined 4.5% and a 30-day share price return that...

(Updates with the company's response in the fourth paragraph.) Super Micro Computer (SMCI) is coo

Chinese consumers have filed a new class-action lawsuit against Tesla (NasdaqGS:TSLA) alleging fraudulent marketing and consumer deception related to its Full Self-Driving feature in China. The case targets Tesla's largest international market and raises questions around how the company presents its advanced driver assistance capabilities. At the same time, Tesla's humanoid robotics and autonomy ambitions face sharper competition as OpenAI launches a robotics division and Nvidia expands its...

Tesla (NasdaqGS:TSLA) is facing a new class-action lawsuit in China alleging false advertising and consumer fraud related to its Full Self-Driving feature. The case challenges how Tesla markets FSD in one of its most important international markets and could influence regulatory scrutiny and consumer sentiment. At the same time, OpenAI, led by Sam Altman, has launched a dedicated robotics division focused on humanoid robots, while Nvidia is accelerating its own robotics efforts. These moves...

C3.ai (NYSE:AI) is back in the chat rooms again this month, up 7.28% in a week as retail traders bet the enterprise AI software story has finally bottomed at $9.28. But here’s what you should actually be watching. The C3.ai story is broken, not bottoming The fundamentals are unraveling beneath the surface. Q3 FY26 revenue ... Forget C3.ai. While It Burns Cash and Faces Lawsuits This 6.74% Yielding Pipeline Giant Is Quietly Powering AI Data Centers

After three weeks of testimony, $134 billion in demands, and a judge who was ready to dismiss the appeal before the ink was dry, Silicon Valley's messiest soap opera is over (for now)